The 'Pushmi-Pullyu' of DNA REPAIR: Clinical Synthetic Lethality.
Maintenance of genomic integrity is critical for adaptive survival in the face of endogenous and exogenous environmental stress. The loss of stability and fidelity in the genome caused by cancer and cancer treatment provides therapeutic opportunities to leverage the critical balance between DNA injury and repair. Blocking repair and pushing damaged DNA through the cell cycle using therapeutic inhibitors exemplify the 'pushmi-pullyu' effect of disrupted DNA repair. DNA repair inhibitors (DNARi) can be separated into five biofunctional categories: sensors, mediators, transducers, effectors, and collaborators that recognize DNA damage, propagate injury DNA messages, regulate cell cycle checkpoints, and alter the microenvironment. The result is cancer therapeutics that takes advantage of clinical synthetic lethality, resulting in selective tumor cell kill. Here, we review recent considerations related to DNA repair and new DNARi agents and organize those findings to address future directions and clinical opportunities.
['Ivy|S Percy|SP|', 'de Bono|Johann|J|', 'Kohn|Elise C|EC|']
D000818:Animals D000970:Antineoplastic Agents D004249:DNA Damage D004260:DNA Repair D006801:Humans D000072020:Synthetic Lethal Mutations
synthetic lethality DNA damage repair DNA damage response genomic instability homologous recombination defects mutational burden